## Zafer Akcali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8365234/publications.pdf

Version: 2024-02-01

1039880 996849 35 236 9 15 citations h-index g-index papers 36 36 36 248 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Treatment of Lymph Node–Negative, Early-Stage HER2-Positive Breast Cancer. Journal of Clinical Oncology, 2016, 34, 639-640.	0.8	1
2	Triple negative breast cancer: Demographic and clinicopathological properties Journal of Clinical Oncology, 2016, 34, e12572-e12572.	0.8	0
3	Combined versus sequential antracycline and taxane adjuvant regimens in triple negative breast cancer patients Journal of Clinical Oncology, 2016, 34, e12578-e12578.	0.8	O
4	Survival Effect of Supportive Care Services for Turkish Patients with Metastatic Gastric Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1213-1217.	0.5	1
5	Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: A pilot study. Oncology Letters, 2014, 7, 255-259.	0.8	13
6	5083 POSTER The Predictive and Prognostic Significance of PTEN, P27 and PI3K Expression in HER2 Overexpressing Metastatic Breast Cancer. European Journal of Cancer, 2011, 47, S355.	1.3	0
7	3530 POSTER The Impact of Early Thromboembolic Event on Overall Survival in Cancer Patients. European Journal of Cancer, 2011, 47, S255.	1.3	O
8	Oxaliplatin-Induced Immune Thrombocytopenia in a Patient with Colon Cancer. American Surgeon, 2011, 77, 9-9.	0.4	21
9	Signet-ring cell carcinoma of the colon with leptomeningeal involvement. Journal of Clinical Neuroscience, 2010, 17, 1051-1053.	0.8	7
10	Cisplatin combination regimen in the second-line treatment of non-small cell lung cancer Journal of Clinical Oncology, 2010, 28, e18136-e18136.	0.8	0
11	The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. Journal of Experimental and Clinical Cancer Research, 2009, 28, 97.	3.5	21
12	Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8. Tumori, 2008, 94, 474-480.	0.6	7
13	Role of c-erbb2 expression in non-small cell lung cancer. Journal of Clinical Oncology, 2008, 26, 22044-22044.	0.8	0
14	Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8. Tumori, 2008, 94, 474-80.	0.6	4
15	t(8;16) AML developed subsequent to breast cancer therapy. Hematology, 2006, 11, 153-155.	0.7	3
16	Value of Whole-Body Turbo Short Tau Inversion Recovery Magnetic Resonance Imaging With Panoramic Table For Detecting Bone Metastases. Journal of Computer Assisted Tomography, 2006, 30, 151-156.	0.5	26
17	Drug interaction between capecitabine and warfarin: a case report and review of the literature. International Journal of Clinical Pharmacology and Therapeutics, 2006, 44, 80-82.	0.3	14
18	MALTOMA Presenting With Thrombocytopenia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 321-322.	0.6	6

#	Article	lF	Citations
19	Prognostic importance of COX-2 expression in patients with colorectal cancer. Pathology Research and Practice, 2005, 201, 497-502.	1.0	25
20	Primary Squamous Cell Carcinoma of the Stomach a Case Report. Tumori, 2005, 91, 440-442.	0.6	10
21	Controversy in Folinic Acid Administration After Fluorouracil. Journal of Clinical Oncology, 2005, 23, 3862-3862.	0.8	O
22	Prognostically Favorable Abdominal Breast Cancer Metastases with Stomach Involvement. Oncology Research and Treatment, 2005, 28, 270-272.	0.8	4
23	Hodgkin′s disease in an elderly patient with B-Cell chronic lymphocytic leukemia. Indian Journal of Cancer, 2005, 42, 158.	0.2	4
24	Acute Myeloid Leukemia 4 Years After Kaposi's Sarcoma in a Renal Transplant Recipient. Oncology Research and Treatment, 2004, 27, 163-165.	0.8	3
25	Joint pain and arthritis in renal transplant recipients and correlation with cyclosporine therapy. Rheumatology International, 2003, 23, 159-162.	1.5	13
26	Treatment results in renal transplant recipients with non-Hodgkin's lymphoma. Transplantation Proceedings, 2003, 35, 1404-1407.	0.3	2
27	Cost-Effectiveness of Chemotherapy in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 3750-3752.	0.8	4
28	Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer, 2002, 95, 2038-2039.	2.0	0
29	Prognostic Importance of Tumor Angiogenesis in Breast Carcinoma with Adjuvant Chemotherapy. Pathology Research and Practice, 2002, 198, 7-12.	1.0	9
30	The Clinicopathologic Characteristics of Colorectal Cancer in Patients under 50 years of Age: Experience of an Oncology Center. Tumori, 2001, 87, 74-77.	0.6	7
31	Comment on: granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1373.	0.4	1
32	Cisplatin plus Vinorelbine as a Salvage Regimen in Refractory Breast Cancer. Tumori, 2000, 86, 283-285.	0.6	12
33	Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Preliminary Report. Tumori, 1999, 85, 483-487.	0.6	6
34	Are serum TPS levels important in the prognosis of lung cancer?. European Journal of Cancer, 1997, 33, S49.	1.3	0
35	A Case of Renal Vein Thrombosis with Posterior Nut Cracker Syndrome. Nephron, 1995, 69, 476-477.	0.9	11